SG10201908881PA - Fused bicyclic compounds for the treatment of disease - Google Patents

Fused bicyclic compounds for the treatment of disease

Info

Publication number
SG10201908881PA
SG10201908881PA SG10201908881PA SG10201908881PA SG 10201908881P A SG10201908881P A SG 10201908881PA SG 10201908881P A SG10201908881P A SG 10201908881PA SG 10201908881P A SG10201908881P A SG 10201908881PA
Authority
SG
Singapore
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
Inventor
Raju Mohan
Benjamin Pratt
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of SG10201908881PA publication Critical patent/SG10201908881PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

FUSEDBICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE OF THE DISCLOSURE Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease. --
SG10201908881P 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease SG10201908881PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26

Publications (1)

Publication Number Publication Date
SG10201908881PA true SG10201908881PA (en) 2019-11-28

Family

ID=56072361

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201908881P SG10201908881PA (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease
SG11201707610PA SG11201707610PA (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707610PA SG11201707610PA (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Country Status (16)

Country Link
US (4) US10421759B2 (en)
EP (2) EP3274350A1 (en)
JP (1) JP6843061B2 (en)
KR (1) KR20180003545A (en)
CN (1) CN107912042A (en)
AU (2) AU2016238523A1 (en)
BR (1) BR112017020374A2 (en)
CA (1) CA2980394A1 (en)
CL (1) CL2017002405A1 (en)
CO (1) CO2017010621A2 (en)
HK (1) HK1249756A1 (en)
IL (1) IL254572A0 (en)
MX (1) MX370897B (en)
RU (2) RU2017137366A (en)
SG (2) SG10201908881PA (en)
WO (1) WO2016151403A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107912042A (en) * 2015-03-26 2018-04-13 阿卡纳治疗学有限公司 For treating the fused bicyclic compound of disease
AU2017270203A1 (en) * 2016-05-25 2019-01-03 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2017205684A1 (en) * 2016-05-25 2017-11-30 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
CN111542319A (en) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 Fused bicyclic compounds
CN108264474B (en) * 2018-02-09 2019-10-25 浙江师范大学 A kind of synthetic method of tryptamines and its derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP4679517B2 (en) * 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド Azepine derivatives as drugs
BRPI0514269A (en) 2004-08-10 2008-06-10 Exelixis Inc heterocyclic compounds as pharmaceutical agents
WO2006109633A1 (en) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited Substituted indole compound
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
JP5399262B2 (en) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー LXR and FXR modulators
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090137554A1 (en) 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
EP2334681A1 (en) 2008-09-26 2011-06-22 Wyeth LLC 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
RU2706007C2 (en) * 2014-11-21 2019-11-13 Акарна Терапьютикс, Лтд. Condensed bicyclic compounds for treating disease
RU2021100040A (en) * 2014-12-22 2021-02-02 Акарна Терапьютикс, Лтд. CONDENSED BICYCLIC COMPOUNDS FOR DISEASE TREATMENT
CN107912042A (en) * 2015-03-26 2018-04-13 阿卡纳治疗学有限公司 For treating the fused bicyclic compound of disease

Also Published As

Publication number Publication date
WO2016151403A1 (en) 2016-09-29
CO2017010621A2 (en) 2018-01-31
MX2017012342A (en) 2018-06-11
SG11201707610PA (en) 2017-10-30
AU2016238523A1 (en) 2017-11-09
EP3274350A1 (en) 2018-01-31
US20180118752A1 (en) 2018-05-03
AU2020256301A1 (en) 2020-11-05
CL2017002405A1 (en) 2018-04-27
JP6843061B2 (en) 2021-03-17
US20230002394A1 (en) 2023-01-05
CN107912042A (en) 2018-04-13
HK1249756A1 (en) 2018-11-09
KR20180003545A (en) 2018-01-09
EP3715348A1 (en) 2020-09-30
RU2017137366A3 (en) 2019-07-17
RU2017137366A (en) 2019-04-26
JP2018510876A (en) 2018-04-19
MX370897B (en) 2020-01-09
US10421759B2 (en) 2019-09-24
BR112017020374A2 (en) 2018-06-05
US20200079782A1 (en) 2020-03-12
RU2021107054A (en) 2021-03-31
CA2980394A1 (en) 2016-09-29
IL254572A0 (en) 2017-11-30
US20210214362A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MY192927A (en) Fused bicyclic compounds for the treatment of disease
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
MX2017008456A (en) Fused bicyclic compounds for the treatment of disease.
IL264156A (en) Compounds, compositions, and methods for the treatment of disease
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
MX2017006217A (en) Modulatory polynucleotides.
HK1256795A1 (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
HK1259372A1 (en) Therapeutic compounds, compositions and methods of use thereof
CO2017010621A2 (en) Fused bicyclic compounds for the treatment of diseases
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
IL263177A (en) Fused bicyclic compounds for the treatment of disease
HK1258765A1 (en) Therapeutic compounds, compositions and methods of use thereof